Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$9.6 million.

  • Xeris Biopharma Holdings' Change in Account Payables rose 20.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 24.96%. This contributed to the annual value of -$9.6 million for FY2024, which is 238.14% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Change in Account Payables stood at -$9.6 million for FY2024, which was down 238.14% from $7.0 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Account Payables ranged from a high of $7.0 million in FY2023 and a low of -$9.6 million during FY2024.
  • Over the past 3 years, Xeris Biopharma Holdings' median Change in Account Payables value was -$4.3 million (recorded in 2022), while the average stood at -$2.3 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 322.33% in 2021, then crashed by 238.14% in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Account Payables (Yearly) stood at -$2.5 million in 2020, then soared by 322.33% to $5.5 million in 2021, then plummeted by 178.13% to -$4.3 million in 2022, then surged by 261.16% to $7.0 million in 2023, then crashed by 238.14% to -$9.6 million in 2024.